All News

Urology drugs and devices that are in the pipeline from Auxilium Pharmaceuticals, Inc., Bavarian Nordic, Antares Pharma, Inc., Endo Pharmaceuticals, Bioniche Life Sciences, Inc., and Pfizer Inc.

Prostate cancer research using whole genome sequencing analysis may lead to the identification of novel therapeutic targets as well as diagnostic tools for identifying aggressive primary tumors and characterizing genomic changes associated with disease progression.

The newest urology products and services from Thermo Fisher, Cardinal Health, Coker Group, and Dale Medical Products, Inc.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. interstitial cystitis trials that are currently recruiting participants as well as phase IV U.S. incontinence/overactive bladder trials. This list is current as of March 11, 2011. For more information, view the complete database at http://ClinicalTrials.gov.

Using tissue samples from primary renal tumors and matching resected or biopsied metastatic deposits, researchers reported new insights into determining which patients may benefit most from such mTOR inhibitors as temsirolimus (Torisel) and everolimus (Afinitor).

A multicenter study comparing aneuploidy rates between concurrent ejaculated and testicular spermatozoa from the same individual reveals lower DNA damage but higher aneuploidy rates among testicular spermatozoa of men with persistently high sperm DNA damage.

With Republicans in control of the House of Representatives, there is some potential good news and bad news for physicians, including urologists, as the drive to slash the federal deficit moves into high gear.

Urologists are expected to spend more money on building a solid infrastructure and expanding technology at a time when many are concerned about practice economics. Fortunately, there are some actions you can take to improve practice finances.